Logo image of CODX

CO-DIAGNOSTICS INC (CODX) Stock Fundamental Analysis

NASDAQ:CODX - Nasdaq - US1897631057 - Common Stock - Currency: USD

0.288  0 (-0.69%)

After market: 0.2886 +0 (+0.21%)

Fundamental Rating

3

CODX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 188 industry peers in the Health Care Equipment & Supplies industry. The financial health of CODX is average, but there are quite some concerns on its profitability. CODX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

CODX had negative earnings in the past year.
In the past year CODX has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: CODX reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: CODX reported negative operating cash flow in multiple years.
CODX Yearly Net Income VS EBIT VS OCF VS FCFCODX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

1.2 Ratios

CODX's Return On Assets of -58.81% is on the low side compared to the rest of the industry. CODX is outperformed by 71.28% of its industry peers.
CODX has a Return On Equity of -69.30%. This is comparable to the rest of the industry: CODX outperforms 42.55% of its industry peers.
Industry RankSector Rank
ROA -58.81%
ROE -69.3%
ROIC N/A
ROA(3y)-35.82%
ROA(5y)-4.97%
ROE(3y)-40.94%
ROE(5y)-6.37%
ROIC(3y)N/A
ROIC(5y)N/A
CODX Yearly ROA, ROE, ROICCODX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400 600

1.3 Margins

Looking at the Gross Margin, with a value of 74.48%, CODX belongs to the top of the industry, outperforming 87.23% of the companies in the same industry.
In the last couple of years the Gross Margin of CODX has grown nicely.
The Profit Margin and Operating Margin are not available for CODX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.47%
GM growth 5Y9.36%
CODX Yearly Profit, Operating, Gross MarginsCODX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K

More info and screens

6

2. Health

2.1 Basic Checks

CODX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CODX has been increased compared to 1 year ago.
Compared to 5 years ago, CODX has more shares outstanding
There is no outstanding debt for CODX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CODX Yearly Shares OutstandingCODX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
CODX Yearly Total Debt VS Total AssetsCODX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

CODX has an Altman-Z score of -1.66. This is a bad value and indicates that CODX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.66, CODX is doing worse than 62.77% of the companies in the same industry.
CODX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.66
ROIC/WACCN/A
WACC9.11%
CODX Yearly LT Debt VS Equity VS FCFCODX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 4.41 indicates that CODX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.41, CODX is in the better half of the industry, outperforming 66.49% of the companies in the same industry.
A Quick Ratio of 4.27 indicates that CODX has no problem at all paying its short term obligations.
With a decent Quick ratio value of 4.27, CODX is doing good in the industry, outperforming 70.74% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.41
Quick Ratio 4.27
CODX Yearly Current Assets VS Current LiabilitesCODX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 19.70% over the past year.
Looking at the last year, CODX shows a very negative growth in Revenue. The Revenue has decreased by -42.52% in the last year.
CODX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 79.52% yearly.
EPS 1Y (TTM)19.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.58%
Revenue 1Y (TTM)-42.52%
Revenue growth 3Y-65.8%
Revenue growth 5Y79.52%
Sales Q2Q%-89.25%

3.2 Future

CODX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.12% yearly.
CODX is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -42.90% yearly.
EPS Next Y17.86%
EPS Next 2Y30.12%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-77.06%
Revenue Next 2Y-42.9%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CODX Yearly Revenue VS EstimatesCODX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
CODX Yearly EPS VS EstimatesCODX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.5 -0.5 1 -1 1.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CODX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CODX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CODX Price Earnings VS Forward Price EarningsCODX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CODX Per share dataCODX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

CODX's earnings are expected to grow with 30.12% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.12%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CODX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CO-DIAGNOSTICS INC

NASDAQ:CODX (5/29/2025, 8:00:00 PM)

After market: 0.2886 +0 (+0.21%)

0.288

0 (-0.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-06 2025-08-06
Inst Owners18.02%
Inst Owner Change1.53%
Ins Owners6.7%
Ins Owner Change0%
Market Cap9.71M
Analysts43.33
Price Target1.02 (254.17%)
Short Float %0.45%
Short Ratio0.78
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.56%
Min EPS beat(2)-3.81%
Max EPS beat(2)4.93%
EPS beat(4)2
Avg EPS beat(4)4.01%
Min EPS beat(4)-44.72%
Max EPS beat(4)59.63%
EPS beat(8)4
Avg EPS beat(8)-13.81%
EPS beat(12)6
Avg EPS beat(12)-44.67%
EPS beat(16)10
Avg EPS beat(16)-18.04%
Revenue beat(2)1
Avg Revenue beat(2)3.29%
Min Revenue beat(2)-61.05%
Max Revenue beat(2)67.62%
Revenue beat(4)2
Avg Revenue beat(4)129.06%
Min Revenue beat(4)-84.96%
Max Revenue beat(4)594.64%
Revenue beat(8)3
Avg Revenue beat(8)188.65%
Revenue beat(12)4
Avg Revenue beat(12)110.49%
Revenue beat(16)6
Avg Revenue beat(16)85.66%
PT rev (1m)0%
PT rev (3m)-33.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.94%
EPS NY rev (1m)0%
EPS NY rev (3m)22.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.25%
Revenue NY rev (1m)-36.67%
Revenue NY rev (3m)-36.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.48
P/FCF N/A
P/OCF N/A
P/B 0.18
P/tB 0.34
EV/EBITDA N/A
EPS(TTM)-1.06
EYN/A
EPS(NY)-0.35
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.86
OCFYN/A
SpS0.12
BVpS1.61
TBVpS0.84
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -58.81%
ROE -69.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.48%
FCFM N/A
ROA(3y)-35.82%
ROA(5y)-4.97%
ROE(3y)-40.94%
ROE(5y)-6.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.47%
GM growth 5Y9.36%
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 54.34%
Cap/Sales 19.12%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.41
Quick Ratio 4.27
Altman-Z -1.66
F-Score3
WACC9.11%
ROIC/WACCN/A
Cap/Depr(3y)92.34%
Cap/Depr(5y)204.81%
Cap/Sales(3y)14.45%
Cap/Sales(5y)9.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.58%
EPS Next Y17.86%
EPS Next 2Y30.12%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-42.52%
Revenue growth 3Y-65.8%
Revenue growth 5Y79.52%
Sales Q2Q%-89.25%
Revenue Next Year-77.06%
Revenue Next 2Y-42.9%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y6.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-27.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.03%
OCF growth 3YN/A
OCF growth 5YN/A